Blinatumomab New Treatment Option for Pediatric B-Cell Precursor ALL

Single-agent blinatumomab demonstrated antileukemia activity in pediatric patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in a recently published phase I/II study.

Source: CancerNetwork - November 15, 2016 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Leukemia & Lymphoma News Pediatric Cancers Source Type: news